echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > IGF1 gene therapy slows reproductive aging in middle-aged female rats by affecting hypothalamic GnRH and kisspeptin neurons

    IGF1 gene therapy slows reproductive aging in middle-aged female rats by affecting hypothalamic GnRH and kisspeptin neurons

    • Last Update: 2022-11-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
          

       

    Image: Figure 7
    .
    Effects
    of IGF1 gene therapy on microglial activation status.


    "Based on our findings, we propose IGF1 gene therapy to delay reproductive aging as a potential strategy
    to optimize longevity and combat age-related health problems in women.
    "

    A new research paper published on the cover of Aging (listed as "Aging (Albany NY)" by Medline/PubMed and "Aging- us" by Web of Science), Volume 14, Issue 21, titled "IGF1 gene therapy in middle-aged female rats delays reproductive senescence.
    " through its effects on hypothalamic GnRH and kisspeptin neurons
    。 ”

    The process of aging is the result of a gradual loss of homeostasis and impairment of bodily functions, including the central nervous system, where the hypothalamus plays a key role
    in regulating the mechanisms of aging.
    Consequences of aging include the chronic pro-inflammatory environment of the hypothalamus, which leads to a decrease in the secretion of gonadotropin-releasing hormone (GnRH) and impairs the function
    of kisspeptin neurons.

    In the new study, the researchers analyzed the effects of insulin-like growth factor 1 (IGF1) gene therapy on hypothalamic kisspeptin/GnRH neurons and microglia, which mediate inflammatory processes
    associated with the aging process.

    "The objective of this study is to investigate the effects
    of IGF1 gene therapy on the estrous cycle, kisspeptin and GnRH neurons, and microglia in middle-aged female rats.
    "

    The results showed that kisspeptin expression was higher in the anterior ventral periventricular (AVPV) nucleus of IGF1 rats, and higher GnRH immunoactivity in the arcuate nucleus and middle bulge region
    .
    In addition, the number of Iba1+ microglia and MHCII+/Iba1+ in IGF1-treated animals AVPV and arcuate nucleus increased
    .
    In summary, IGF1 gene therapy maintained the generation of kisspeptin in the AVPV nucleus of middle-aged female rats, induced the release of GnRH in the middle bulge region, and changed the number and reactivity
    of microglia.
    The researchers believe that IGF1 gene therapy may have a protective effect
    against decreased reproductive capacity.

    "Based on our findings, we propose IGF1 gene therapy to delay reproductive aging as a potential strategy
    to optimize longevity and combat age-related health problems in women.
    "

    IGF1 gene therapy in middle-aged female rats delays, reproductive senescence through its effects on hypothalamic, GnRH and kisspeptin neurons


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.